Over the past few years, both Brazil and Venezuela have witnessed an increase in the production, growth, and acceptance of generic medicines in their respective healthcare systems.
Generic drugs represent a great advance both in Brazil and Mexico, as they allow the population to access affordable, safe and effective treatments.
The US Food and Drug Administration’s (FDA) one-year progress report for the Generic Drug Cluster – a multi-country forum on generic drugs – explains the purpose of the Cluster and key achievements made so far.
Brazil is a country active in life sciences research, publications, manufacturing and exports. Biosimilars have the highest growth potential for the pharmaceutical sector in Latin America .
Argentina has an important pharmaceutical sector, being the third largest market in Latin America after Brazil and Mexico. Pharmaceutical companies from Denmark, France, Germany, Switzerland, the UK and the US are stablished in Argentina. Argentine market has extensive experience in the incorporation of foreign investments for the sector as well as offers multiple business opportunities.
According to a research carried out by Vargas V, et al. 2022, pharmaceutical innovations, together with higher living standards and more effective public health interventions, have been significantly important to extend life expectancy and improve population quality of life in Latin America and the Caribbean .
Canada has made a federal budget commitment to supporting a national pharmacare programme. This can be bolstered through strengthening Canada’s domestic generics pharmaceutical industry.
The United Kingdom’s (UK) National Health Service (NHS) faces shortages of blood pressure pills, painkillers and antidepressants due to drug manufacturer supply problems.
Many Americans require prescription drugs on a daily basis. With year-on-year price increases of branded products, turning to pharmacists for advice could reduce the financial strain on households [1, 2].
The US Food and Drug Administration’s (FDA) Office of Generic Drugs annual report reveals the importance of innovation and scientific collaboration in advancing the generic drug programme in 2021.